

OLEPTAL DT

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for **OLEPTAL DT** [Oxcarbazepine 150mg, 300mg and 450mg dispersible uncoated Tablet] [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Oxcarbazepine produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of seizure spread in the intact brain.

INDICATION: For use as monotherapy and adjunctive therapy in the treatment of partial seizures in adult patients with epilepsy. It is also indicated as adjunctive therapy in the treatment of partial seizures in children in the age group of 4-16 years with epilepsy.

DOSAGE AND ADMINISTRATION: Oleptal DT is recommended as adjunctive and monotherapy in the treatment of partial seizures in adults and as adjunctive treatment for partial seizures in children 4 -16 years of age group. All dosing should be given in a twice a day (BID) regimen and can be given with or without food.

CONTRAINDICATION: Oxcarbazepine should not be used in patients with a known hypersensitivity to oxcarbazepine or to any of its components.

WARNINGS & PRECAUTIONS: Use cautiously and stop the Oleptal DT in patients with hyponatremia, anaphylactic reactions and angioedema, with a past history of hypersensitivity reaction to carbamazepine, serious dermatological reactions, association with HLA-B*1502, suicidal behavior and ideation, multi-organ hypersensitivity, hematologic events and seizure control during pregnancy. Drug reaction with eosinophilia and systemic symptoms (DRESS)/multi-organ hypersensitivity and cognitive/neuropsychiatric adverse events then oxcarbazepine should be discontinued

DRUG INTERACTIONS: Antiepileptic drugs: carbamazepine, phenobarbital, phenytoin, valproic acid and hormonal contraceptives, calcium antagonists, cimetidine, erythromycin and dextropropoxyphene.

ADVERSE REACTIONS: Dizziness, diplopia, ataxia, vomiting, nausea, somnolence, headache, asthenia, edema legs, weight increase, hypotension, diarrhea, dyspepsia, constipation, gastritis, muscle weakness, insomnia, rhinitis, acne, vertigo, abnormal vision, tremor, abnormal gait, rash, hyponatremia, somnolence, diplopia, dizziness, fatigue, nystagmus, withdrawal symptoms like convulsions, status epilepticus and ataxia.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/OLEPTAL DT 150,300,450 mg/Oct-2015/01/ABPI

(Additional information is available on request)